-iCAD, Inc. (Nasdaq:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today reported financial results for the three and nine months ended September 30, 2014.
“Our strong financial results in the third quarter underscore the considerable progress we have made in the radiation therapy and cancer detection areas. Also, the acquisitions of DermEbx and Radion in mid-July contributed significantly, resulting in recurring revenue more than doubling over the same period last year,” stated Ken Ferry, President and Chief Executive Officer of iCAD.
Help employers find you! Check out all the jobs and post your resume.
